Exciva secures €51 million Series B as EQT doubles down on neuroscience
EQT Life Sciences has reinforced its long-term commitment to brain health by co-leading a €51 million Series B funding round in German biotech company Exciva, a clinical-stage specialist focused on treating neuropsychiatric symptoms in Alzheimer’s disease and other neurodegenerative disorders.
The fresh capital is set to accelerate the development of Exciva’s lead candidate, an orally available small molecule designed to tackle some of the most debilitating behavioral symptoms experienced by patients, including agitation, anxiety and aggression. These symptoms are a major driver of caregiver burden and institutionalization, yet remain poorly addressed by current therapies.
EQT Life Sciences deepens its footprint in brain health
With this investment, EQT Life Sciences continues to build a focused portfolio across neuroscience and neurodegeneration, areas historically seen as high risk but now benefiting from rapid advances in biology, biomarkers and trial design. The firm, part of global investment group EQT, has been steadily increasing exposure to companies targeting central nervous system (CNS) disorders, reflecting a belief that the field is entering a new phase of scientific and commercial maturity.
Industry analysts note that the backing of an investor with EQT’s scale and sector expertise sends a strong signal about confidence in Exciva’s science and its potential route to market. The Series B round is expected to fund key late-stage clinical milestones that could substantially de-risk the program.
Exciva’s focus: neuropsychiatric symptoms in Alzheimer’s
While recent drug approvals have concentrated on slowing cognitive decline by targeting amyloid or tau pathology, Exciva is taking aim at the neuropsychiatric dimensions of Alzheimer’s disease, which often emerge early and intensify as the condition progresses. These symptoms can lead to higher use of emergency care, faster transition to nursing homes and significant emotional strain on families.
A differentiated mechanism of action
Exciva’s lead compound is understood to modulate specific neurotransmitter pathways implicated in mood, arousal and behavior, with the goal of restoring balance without the heavy side-effect burden associated with traditional antipsychotics or sedatives. Conventional off-label treatments can increase the risk of falls, cardiovascular events and mortality in elderly patients.
By contrast, Exciva is developing a targeted approach intended to preserve patient alertness and functional capacity while reducing episodes of agitation and aggression. If successful in late-stage trials, the therapy could be positioned as a first-line option for managing behavioral symptoms in Alzheimer’s and potentially other forms of dementia.
How the €51M Series B will be used
The €51 million Series B financing will primarily support:
- Expansion of ongoing and planned Phase II and Phase III clinical trials in Alzheimer’s patients with pronounced neuropsychiatric symptoms.
- Broader biomarker and digital assessment programs to objectively measure agitation, sleep patterns and daily activity.
- Scaling of manufacturing and CMC (chemistry, manufacturing and controls) capabilities in preparation for potential registration trials and commercialization.
- Regulatory interactions in key markets, including the European Medicines Agency and the U.S. Food and Drug Administration.
The funding is also expected to strengthen Exciva’s internal capabilities in clinical operations, pharmacovigilance and market access, laying the groundwork for a potential partnership or independent launch strategy depending on future trial outcomes.
Addressing a critical unmet medical need
More than 55 million people worldwide are estimated to be living with dementia, according to the World Health Organization, and that figure is projected to rise sharply as populations age. Up to 90% of these patients will experience neuropsychiatric symptoms at some point during the course of the disease, yet treatment options remain limited and often unsatisfactory.
Health systems currently rely heavily on non-pharmacological interventions and off-label use of older psychiatric medications. These approaches can be inconsistent, resource-intensive and clinically risky. A safe, effective and purpose-built therapy for agitation and related symptoms would address a substantial gap in the neuropsychiatry toolkit and could reshape standards of care in long-term and community settings.
Strategic implications for the neuroscience investment landscape
The Exciva Series B round adds to a growing wave of capital flowing into companies targeting CNS disorders, a domain that for years struggled to attract sustained investment due to high clinical failure rates. Recent scientific breakthroughs, coupled with improved clinical trial design and more precise patient stratification, are now changing investor perceptions.
For EQT Life Sciences, co-leading this financing underscores a conviction that focused, data-driven bets in neuroscience can generate both meaningful patient impact and long-term value. For Exciva, the backing of a globally recognized life sciences investor is likely to enhance its visibility among potential partners, regulators and clinical investigators.
What to watch next
Key milestones to monitor over the next 12–24 months include:
- Readouts from mid- to late-stage trials assessing the impact of Exciva’s candidate on agitation severity, caregiver burden and quality-of-life metrics.
- Safety and tolerability data in broader, more diverse patient populations, including those with multiple comorbidities.
- Potential expansion into related indications such as agitation in Parkinson’s disease dementia or frontotemporal dementia.
- Strategic collaborations with larger pharmaceutical companies to support global development and commercialization.
If Exciva’s program delivers on its clinical promise, the company could emerge as a central player in a new generation of targeted treatments for the behavioral dimensions of neurodegenerative disease, an area that has long been overshadowed by the focus on memory and cognition. The latest investment from EQT Life Sciences signals that this once-neglected frontier of neuroscience is now firmly on the radar of major life sciences investors.